Startseite Kongressberichte & Archiv 2021 ASCO Annual Meeting Urogenital Cancer Genitourinary Cancer—Prostate, Testicular, and Penile

Genitourinary Cancer—Prostate, Testicular, and Penile

Alistair Grey, Rebecca Scott, Bina Shah, et al.
The study authors conclude that the CADMUS trial shows multi-parametric ultrasound has a diagnostic performance approaching that of multiparametric MRI and significant cancer detection is improved by the use of both scans over multiparametric MRI alone. Clinical trial information: 38541912.
Taimur T. Shah, Abi Kanthabalan, Menelaos Pavlou, et al.
The study authors demonstrate that Prostate multiparametric MRI and MRI-targeted biopsies can accurately detect and localize recurrent prostate cancer following radiotherapy. They further show that focal ablation to areas of intra-prostatic recurrence preserves continence in the majority of men with good cancer control. Clinical trial information: NCT01883128
Alan Dal Pra, Pirus Ghadjar, Stefanie Hayoz, et al.
The study authors showed that this first contemporary randomized controlled trial in patients with recurrent prostate cancer treated with early SRT without ADT has validated the prognostic utility of the GC. The further demonstrated that independent of standard clinicopathologic variables and radiotherapy dose, patients with a high-GC were more than twice as likely than a lower GC score to experience biochemical and clinical progression and receive salvage androgen deprivation therapy. They conclude, that the data confirm the clinical value of Decipher GC for tailoring treatment in the postoperative salvage setting.
Anthony Victor D'Amico, Wanling Xie, Elizabeth McMahon, et al.
The study authors conclude that adding docetaxel to ADT+RT did not prolong overall survival in men with unfavorable-risk prostate carcinoma. However, it decreased the RT-induced cancer incidence and may prolong overall survival in the subgroup of men with a PSA < 4 ng/mL by reducing PCSM. Clinical trial information: NCT00116142
Sean Matthew McBride, Daniel Eidelberg Spratt, Marisa Kollmeier, et al.
The study authors  demonstrated in the AASUR-study impressive 3-yr bRFS, rapid T recovery, and limited toxicities. The safety profile of this regimen was consistent with the known AE profile of the androgen receptor signaling inhibitors andadiation therapy. The authors recommend for this regimen a further, randomized evaluation. Clinical trial information: NCT02772588
Johann S. De Bono, Lawrence Fong, Tomasz M. Beer, et al.
HPN424 is a novel half-life extended PSMA-targeting T cell engager. The study authors conclude that this once weekly treatment was well tolerated with transient and manageable adverse events, that were consistent with the class of agent. Grade 3 cytokine release syndrom was observed in 4% of patients, occurring with the first administration of the target dose. Evidence of antitumor activity was demonstrated with PSA and CTC reductions and treatment duration > 24 weeks in 15/62 patients. The authors mention the encouraging signals that were seen at the highest fixed-dose cohort including a confirmed RECIST partial response. Clinical trial information: NCT03577028
Mark Christopher Markowski, Mary-Ellen Taplin, Rahul Raj Aggarwal, et al.
The study authors conclude that bipolar androgen therapy with intramuscular testosterone plus nivolumab was well-tolerated without safety signals of concern. Bipolar androgen therapy plus nivolumab met the pre-specified primary endpoint of confirmed PSA50 response in a heavily treated population. Durable responses were observed in a subset of patients. There is an ongoing Biomarker analysis to identify a molecular signature predictive of response. Clinical trial information: NCT03554317
Scott T. Tagawa, Michael Sun, A. Oliver Sartor, et al.
The study authors conclude that PSMA-targeted alpha-emitter 225Ac utilizing intact antibody J591 is tolerable with early evidence of clinical activity. Clinical trial information: NCT03276572
Shirin Ardeshirrouhanifard, Sophie Fosså, Robert A Huddart, et al.
The study authors conclude that discrepancies between patient-reported and audiometrically-defined HL after cisplatin-based chemotherapy are associated with several factors including age, education, tinnitus, prior noise exposure, use of hearing aids, and conductive HL.
Darren R. Feldman, Akeem Ronell Lewis, Andrea Knezevic, et al.
The study authors demonstrate in this first assessment of vaccine titers following HDCT/ASCT for germ cell tumors, that HDCT/ASCT does not result in loss of immunity to childhood vaccines and that GCT patients retain protective titers more frequently than those with Hodgkin lymphoma. Important, 15-31% of germ cell tumor patients lack MMR immunity at baseline and at 1-year post-ASCT. The study authors recommend checking MMR titers at 1-year post-ASCT with revaccination of those lacking immunity, however, titer evaluation and revaccination is not necessary for other childhood immunizations.
Jennifer King, Sandra K. Althouse, Clint Cary, et al.
The study authors conclude that patients with metastatic NSGCT who achieve complete response after 1st-line chemotherapy can be safely observed with surveillance. Most patients who relapse can be salvaged with surgery and/or chemotherapy.
Andreas Georg Wibmer, Darren R. Feldman, Carol Chen, et al.
The study authors conclude that In male germ cell tumor patients, central adiposity at baseline increases cardiometabolic risk after cisplatin-based chemotherapy, particularly for obese individuals. They recommend quantification of an individual’s body fat distribution on pre-chemotherapy CT which could potentially help to identify high-risk individuals who may benefit from intensified risk-modulating interventions.